TITLE

Turning T cells to the task of fighting cancer

AUTHOR(S)
Moulton, Donalee
PUB. DATE
May 2000
SOURCE
CMAJ: Canadian Medical Association Journal;5/30/2000, Vol. 162 Issue 11, p1604
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on research being done at Memorial Sloan-Kettering Cancer Center in New York City to stimulate T lymphocyte cells to fight cancer. The minimal components needed to make genetically engineered cells that are potent activators of T cells that are able to recognize and destroy tumor cells; The effectiveness of the artificial antigen-presenting cells; Comments by lead researcher Dr. Michel Sadelian.
ACCESSION #
3168026

 

Related Articles

  • Training the Body To Fight Cancer.  // Time;9/14/2009, Vol. 174 Issue 10, p34 

    The article discusses how cancer vaccines are designed to assist the human immune system in detecting and attacking cancer. Options for doing so are noted including targeting growing tumors, suppressing cancer cells that suppress the immune system, training T cells to recognize cancer cells, and...

  • Training the Body To Fight Cancer.  // Time International (Atlantic Edition);9/14/2009, Vol. 174 Issue 10, p28 

    The article discusses how cancer vaccines are designed to assist the human immune system in detecting and attacking cancer. Options for doing so are noted including targeting growing tumors, suppressing cancer cells that suppress the immune system, training T cells to recognize cancer cells, and...

  • Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. Homma, Sadamu; Toda, Gotaro; Gong, Jianlin; Kufe, Donald; Ohno, Tsuneya // Journal of Gastroenterology;2001, Vol. 36 Issue 11, p764 

    Background. The prevention of recurrence of hepatocellular carcinoma (HCC) after treatment is very important for improvement of the prognosis of HCC patients. Dendritic cells (DCs) are potent antigen-presenting cells that can prime naive T cells to induce a primary immune response. We attempted...

  • NEW LAUNCHES.  // Woman's Era;Jul2012, p130 

    The article offers information on dendritic cell therapy for cancer and the clinical trial being conducted at a hospital India to evaluate the safety and efficacy of APCEDENTM, a dendritic cell formulation, in patient with refractory solid malignancies on symptomatic treatment.

  • Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy plus Autologous Hematopoietic Stem-Cell Transplantation for Metastatic Breast Cancer. Stadtmauer, Edward A.; O'Neill, Anne; Goldstein, Lori J.; Crilley, Pamela A.; Mangan, Kenneth F.; Ingle, James N.; Brodsky, Isadore; Martino, Silvana; Lazarus, Hillard M.; Erban, John K.; Sickles, Cheryl; Luger, Selina M.; Klumpp, Thomas R.; Litzow, Mark R.; Topolsky, David L.; Glick, John H. // New England Journal of Medicine;04/13/2000, Vol. 342 Issue 15, p1069 

    Background: We conducted a randomized trial in which we compared high-dose chemotherapy plus hematopoietic stem-cell rescue with a prolonged course of monthly conventional-dose chemotherapy in women with metastatic breast cancer. Methods: Women 18 to 60 years of age who had metastatic breast...

  • A stem-cell treatment success story. Lindsey, Jackie // Our Sunday Visitor;2/6/2011, Vol. 99 Issue 41, p14 

    The article details the story of Don Lindsey whose stage 4 cancer was cured using adult stem-cells.

  • Breast cancer breakthrough. James, Caron // Woman's Day (Australia Edition);7/8/2002, p48 

    Profiles cancer patient Raoulla Saisanas. Details on the treatment of her cancer through stem-cell therapy in a clinical trial at Peter MacCallum Center in Melbourne, Victoria; Personal background.

  • Fusion induces tumour rejection. Hart, Ian; Colaco, Camilo // Nature;8/14/1997, Vol. 388 Issue 6643, p626 

    Discusses research by Kufe, et al, in `Nature Medicine,' which used a simple strategy for cancer treatment using immunotherapy. Renewed optimism for immunotherapy based on better understanding of cytotoxic T lymphocytes (CTL); Review of recent experiments using dendritic cells to present tumor...

  • Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment. Beatty, Gregory L.; Moon, Edmund K. // OncoImmunology;Nov2014, Vol. 3 Issue 11, pN.PAG 

    Chimeric antigen receptor (CAR) modified T cells have shown early promise in hematological malignancies. However, in solid malignancies CAR T cells must overcome a distinct immunosuppressive microenvironment which may compromise their capacity to mediate antitumor activity.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics